Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olvi-Vec in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime)
NCT05281471Phase 3Recruiting
- Sponsor
- Genelux Corporation
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of olvimulogene nanivacirepvec in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Genelux Corporation. Started Aug 2022; status: recruiting.
02
Drugs
olvimulogene nanivacirepvec
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05281471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281471.